We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FibroGen Initiates Phase 2 Trial Testing Pamrevlumab as a COVID-19 Treatment
FibroGen Initiates Phase 2 Trial Testing Pamrevlumab as a COVID-19 Treatment
FibroGen has initiated a phase 2 trial of its monoclonal antibody pamrevlumab for the treatment of hospitalized patients with acute COVID-19 infections.